Bookkeeping Service Providers

  • Accounting
  • Bookkeeping
  • US Taxation
  • Financial Planning
  • Accounting Software
  • Small Business Finance
You are here: Home / Uncategorized / IAMAI writes to Health Ministry against new rules allowing doorstep delivery of medicines

IAMAI writes to Health Ministry against new rules allowing doorstep delivery of medicines

March 30, 2020 by cbn Leave a Comment

Restrictions on online sale of drugs to hurt e-pharmacies, says IAMAI
The new restrictions on online sale of drugs will make doorstep delivery of medicines difficult, according to an industry body which represents various e-pharmacy startups.

The Internet and Mobile Association of India (IAMAI) expressed concerns over the Ministry of Health and Family Welfare’s (MoHFW) circular issued on March 26.

The notification lays down these conditions: that a person licensed to sell and deliver drugs will have to submit an e-mail ID for registration with the licensing authority if prescriptions are to be received through email; the drugs be supplied at the doorstep of the patients located within the same revenue district where the company holding the license to sell is located; and in case of chronic diseases, the prescription will be valid for medicine delivery only if it is presented to the drug retailer within 30 days of its issue. In acute cases, the prescription will be valid only if it is presented to the licensee within seven days of its issue.

The industry lobby said the move could adversely impact delivery of medicines even as drugs fall under essential items which are exempted during the 21-day nationwide lockdown. Pharmeasy, Medlife, 1mg and Netmeds are among the online pharmacy startups operating in India.

Online sale of drugs is often facilitated by e-marketplaces, which are just digital platforms facilitating online transactions between customers and sellers, IAMAI said, adding that services of such platforms may include facilitation of payments, collection, transport or last-mile delivery of the drugs to the customers, or any combination of services therein.

IAMAI argued that these platforms are essentially intermediaries and are not expected to hold a license in Form-20 or Form-21 under the Drugs and Cosmetics Rules, 1945, and such licenses are held by businesses involved in selling drugs and medicines.

“The notification fails to take into consideration the role played by digital intermediaries as it only recognizes agencies with license under Form-20 or Form-21 to engage in the act of online sales and distribution of medicines,” it said.

The provision to allow medicines to be delivered only if available within the same revenue district will likely deprive customers from being able to access important medications if they are not available in the same area as the customer, it said. “This direction is against the interest of the general public at large and against the notion of access to medicines for all. The said proviso does not leave any alternative for the general public in case medicines are not available with the same revenue district.”

IAMAI also expressed reservations about the chronic disease prescription not being valid after more than 30 days. Chronic medication is required by patients over the long term, and in these circumstances (under lockdown) it is unreasonable to expect them to get a new prescription each month, it said.

The industry lobby, in its recommendation to the ministry, suggested that the notification must give due recognition to online marketplaces and the role played by such platforms in facilitating and realizing online transactions of drugs and medicines by excusing them from any licensing for their activities.

It also added that the geographical restriction on sales of drugs, especially in times of the present crisis, be revoked to allow digital services to bring greater efficiencies in supply chain logistics of essential commodities like medicines.

It suggested that the time period restriction on the validity of prescription for chronic diseases be relaxed considering the present exigencies and all forms of digital communications including but not limited to social media platforms, e-mail and other forms of digital communications be given validity for the sharing of prescriptions.

“The present dilemma created by the notification regarding the sale of drugs based on conditions highlighted is against the premise of the e-pharma industry and creates immediate concerns given the emergency arising due to pandemic COVID-19. IAMAI hopes that the industry concerns are given due consideration before the implementation of the suggested provisions,” it said.

Share on FacebookShare on TwitterShare on Google+Share on LinkedinShare on Pinterest

Filed Under: Uncategorized

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Archives

  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • May 2021
  • April 2021
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • March 2016

Recent Posts

  • How Azure Cobalt 100 VMs are powering real-world solutions, delivering performance and efficiency results
  • FabCon Vienna: Build data-rich agents on an enterprise-ready foundation
  • Agent Factory: Connecting agents, apps, and data with new open standards like MCP and A2A
  • Azure mandatory multifactor authentication: Phase 2 starting in October 2025
  • Microsoft Cost Management updates—July & August 2025

Recent Comments

    Categories

    • Accounting
    • Accounting Software
    • BlockChain
    • Bookkeeping
    • CLOUD
    • Data Center
    • Financial Planning
    • IOT
    • Machine Learning & AI
    • SECURITY
    • Uncategorized
    • US Taxation

    Categories

    • Accounting (145)
    • Accounting Software (27)
    • BlockChain (18)
    • Bookkeeping (205)
    • CLOUD (1,322)
    • Data Center (214)
    • Financial Planning (345)
    • IOT (260)
    • Machine Learning & AI (41)
    • SECURITY (620)
    • Uncategorized (1,284)
    • US Taxation (17)

    Subscribe Our Newsletter

     Subscribing I accept the privacy rules of this site

    Copyright © 2025 · News Pro Theme on Genesis Framework · WordPress · Log in